A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies

scientific article published on 11 February 2012

A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2012.01.055
P698PubMed publication ID22330127

P2093author name stringWei Pan
Jie Cao
Zhenyu Zhu
Guangguo Tan
Yifeng Chai
Qiuli Chen
Huaqun Zhang
Wenting Liao
P2860cites workStructural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAVQ27652984
HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic regionQ28252310
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTQ28476094
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeysQ33984182
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replicationQ34336210
Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat proteinQ35024694
Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.Q35585108
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?Q37220038
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.Q37347813
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidateQ37661107
The preventive phase I trial with the HIV-1 Tat-based vaccineQ38378021
HIV-1 Tat induces biochemical changes in the serum of miceQ39684517
Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.Q40112826
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconvertersQ43671904
Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.Q43692324
Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteersQ44436413
Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sitesQ44444482
Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptidesQ45572850
Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.Q45722188
Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbitsQ46043845
HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficientlyQ46346144
Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variantsQ46747253
HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopyQ46901892
HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways.Q51571501
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.Q51828622
Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.Q54739903
Comparison of the efficacy of early versus late viral proteins in vaccination against SIVQ56880151
Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08Q57081491
The therapeutic phase I trial of the recombinant native HIV-1 Tat proteinQ57665211
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccineQ59511395
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDSQ61641064
A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell NucleusQ63343005
Full-length HIV-1 Tat protein necessary for a vaccineQ63384219
Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolatesQ71514644
Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptorQ74008668
HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent mannerQ80241849
Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategyQ81034939
P433issue14
P407language of work or nameEnglishQ1860
P304page(s)2453-2461
P577publication date2012-02-11
P1433published inVaccineQ7907941
P1476titleA designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies
P478volume30

Reverse relations

cites work (P2860)
Q34658608Characterization of Tat antibody responses in Chinese individuals infected with HIV-1.
Q35663722Characterization of the antibody response against EV71 capsid proteins in Chinese individuals by NEIBM-ELISA.
Q37419972Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency
Q41468434Identification of a highly conserved surface on Tat variants
Q52608940Non-neutralizing Antibody Responses against VP1 in Enterovirus A, B, C and Rhinovirus A species among Infants and Children in Shanghai.

Search more.